Spots Global Cancer Trial Database for A Bioequivalence Study of Sunitinib Malate Capsules.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Bioequivalence Study of Sunitinib Malate Capsules.
Official Title: A Bioequivalence Study of Sunitinib Malate Capsules in Healthy Volunteers Under Fed Condition.
Study ID: NCT05800106
Study Description
Brief Summary: A randomized, open, two-period, two-sequence crossover trial design used to assess the pharmacokinetics and safety of Sunitinib Malate Capsules in healthy volunteers under fed condition, and compare the bioequivalence of Sunitinib Malate Capsules produced by Pfizer and Chia Tai Tianqing Pharmaceutical Group Co., Ltd, respectively.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: MALE
Healthy Volunteers: Yes
Locations
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
